GW&K Investment Management LLC Grows Stock Position in Syneos Health Inc (NASDAQ:SYNH)

GW&K Investment Management LLC lifted its stake in Syneos Health Inc (NASDAQ:SYNH) by 23.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,125,797 shares of the company’s stock after purchasing an additional 213,112 shares during the period. Syneos Health comprises about 0.8% of GW&K Investment Management LLC’s holdings, making the stock its 19th largest holding. GW&K Investment Management LLC’s holdings in Syneos Health were worth $59,903,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Boston Advisors LLC purchased a new position in Syneos Health in the second quarter valued at $1,257,000. BB&T Corp boosted its holdings in Syneos Health by 8.1% in the second quarter. BB&T Corp now owns 8,749 shares of the company’s stock valued at $448,000 after purchasing an additional 656 shares during the period. Tiverton Asset Management LLC purchased a new position in Syneos Health in the second quarter valued at $279,000. Holocene Advisors LP boosted its holdings in Syneos Health by 19.9% in the second quarter. Holocene Advisors LP now owns 131,140 shares of the company’s stock valued at $6,700,000 after purchasing an additional 21,746 shares during the period. Finally, Parametric Portfolio Associates LLC boosted its holdings in Syneos Health by 18.8% in the second quarter. Parametric Portfolio Associates LLC now owns 301,841 shares of the company’s stock valued at $15,421,000 after purchasing an additional 47,822 shares during the period.

SYNH has been the subject of a number of recent research reports. Credit Suisse Group lifted their target price on Syneos Health from $56.00 to $58.00 and gave the company an “outperform” rating in a report on Friday, August 23rd. Zacks Investment Research lowered Syneos Health from a “buy” rating to a “hold” rating and set a $55.00 target price for the company. in a report on Tuesday, September 10th. UBS Group raised their price target on Syneos Health from $53.50 to $57.00 and gave the company a “neutral” rating in a research note on Thursday, August 29th. KeyCorp raised their price target on Syneos Health from $63.00 to $65.00 and gave the company an “overweight” rating in a research note on Tuesday, September 3rd. Finally, ValuEngine upgraded Syneos Health from a “sell” rating to a “hold” rating in a research note on Wednesday. Five analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Syneos Health has a consensus rating of “Buy” and an average target price of $59.50.

Syneos Health stock traded down $0.04 during midday trading on Friday, reaching $48.00. The company’s stock had a trading volume of 298,800 shares, compared to its average volume of 574,450. Syneos Health Inc has a fifty-two week low of $36.26 and a fifty-two week high of $56.34. The business has a 50-day simple moving average of $52.95 and a 200-day simple moving average of $49.52. The company has a market cap of $5.09 billion, a P/E ratio of 18.32, a P/E/G ratio of 1.67 and a beta of 1.49. The company has a quick ratio of 1.03, a current ratio of 1.03 and a debt-to-equity ratio of 1.02.

Syneos Health (NASDAQ:SYNH) last announced its quarterly earnings data on Thursday, October 31st. The company reported $0.87 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.82 by $0.05. Syneos Health had a return on equity of 10.13% and a net margin of 1.86%. The company had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same quarter in the previous year, the company earned $0.75 EPS. The firm’s revenue for the quarter was up 5.6% compared to the same quarter last year. As a group, equities analysts forecast that Syneos Health Inc will post 2.79 earnings per share for the current year.

Syneos Health Company Profile

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

Recommended Story: Are analyst ratings accurate?

Want to see what other hedge funds are holding SYNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syneos Health Inc (NASDAQ:SYNH).

Institutional Ownership by Quarter for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.